Stage II HR-Positive Invasive Ductal Carcinoma: Dorian's Survivor Story
This breast cancer diagnosis at a glance
- Stage at diagnosis
- Stage II
- Subtype
- Invasive Ductal Carcinoma
- Biomarkers
- ER-positive; PR-positive; HER2-positive
- Sex
- Female
- Treatment
- chemotherapy, surgery and radiation
- Outcome
- Cancer-Free / NED
Treatment course, step by step
- Started with TCHP chemotherapy and had a complete response before surgery
- Monitoring during chemotherapy included 2 heart ultrasounds and 2 MRIs
- Surgery used needle-guided localization and sentinel-node mapping; margins were clear and lymph nodes were negative
- Radiation followed 5 days per week for 4 weeks
- TCHP drug names were not expanded because the source did not state them.
What happened, in summary
Dorian de Salvo was active, working out 5 to 6 times a week, when she began gaining weight without a clear reason. One doctor dismissed her concerns, but another ran blood work that suggested something could be wrong. While traveling for work, Dorian found a lump in her breast in the shower. After several calls and delays getting the right imaging order, mammogram and ultrasound showed something aggressive-looking. She was diagnosed with Stage IIA triple-positive breast cancer, meaning the cancer was ER-positive, PR-positive, and HER2-positive. Lymph nodes did not appear involved at the start. Her treatment began with TCHP chemotherapy. Chemo affected her ability to concentrate, changed her taste and smell, caused fatigue, diarrhea and nausea, and led to hair loss within about 2 weeks. By the time she was ready for surgery, Dorian had a complete response: the lump could no longer be found. Her monitoring during chemotherapy included 2 echocardiograms and 2 MRIs. Surgery used needle-guided wire localization and sentinel-node mapping. She went home the same day and was told margins were clear and lymph nodes were negative. Radiation followed 5 days a week for 4 weeks, with breath-holding to protect her heart and lungs. As of March 2024, she was about 9 months into a treatment path with roughly 4 months still ahead, while encouraging others to stay themselves through care.
Where this story comes from
This is a lay summary of an account first published by The Patient Story. Read the original in full
How we source and attribute stories Accuracy and limitations
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer